secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2026-02-17T23:59:59+00:00
Accession:  0001493152-26-007139
Event type: other_material
Sentiment:  positive
Materiality: 0.35
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bioAffinity Technologies publishes CyPath Lung case study showing 92% sensitivity in small nodules
--------------------------------------------------------------------------------

- CyPath Lung test demonstrated 92% sensitivity, 87% specificity, and 88% accuracy for detecting lung cancer in nodules <2 cm.
- Case study: 59-year-old with 30-year smoking history, COPD, multiple Lung-RADS 3 nodules; negative CyPath result.
- Negative result allowed continued CT surveillance; follow-up CT showed stable nodules, avoiding invasive procedures.
- Company markets test as LDT; case study reinforces clinical utility for reducing anxiety and supporting treatment decisions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226007139/0001493152-26-007139-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226007139/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-007139

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer